Healthcare Facilities & Services

Page 2

S H L Telemedicine Ltd receives the China Food and Drug Administration for marketing of smartheartTM in China

Wednesday, 14 May 2014 01:00am EDT

S H L Telemedicine Ltd:Says it has received the China Food and Drug Administration (CFDA) approval for the marketing of the smartheartTM in China.The smartheartTM has already received marketing approvals in Europe, the U.S. and Japan.

Cancer Genetics inc launches genomic tests for Follicular Lymphoma and Mantle Cell Lymphoma

Monday, 5 May 2014 08:00am EDT

Cancer Genetics Inc:Received CLIA and New York state approvals for clinical use of its proprietary mature B-cell neoplasm array, or MatBA for Follicular Lymphoma and Mantle-Cell Lymphoma.Both tests further extend portfolio in hematologic cancers being developed by CGI and both were developed and validated via a research collaboration with Memorial Sloan-Kettering Cancer Center.Understanding potential outcome for patient is critical in making informed choices about treatment selection, clinical trial involvement and patient management.

Interleukin Genetics Inc secures approval in New York State to offer PerioPredict

Tuesday, 22 Apr 2014 07:00am EDT

Interleukin Genetics Inc:Receives conditional approval from New York State Department of Health to offer, process and report results of PerioPredict Genetic Risk Test for periodontal disease.State of New York is the only U.S. state that requires an independent regulatory review process including technical validation with clinical utility for laboratory developed tests run within a CLIA certified laboratory.As result of New York State approval the PerioPredict test is available to dental providers and their patients in all 50 U.S. states.

TrovaGene presents Clinical data of molecular diagnostic platform to non-invasively track cancer patients' response to therapy

Tuesday, 8 Apr 2014 11:00am EDT

Trovagene Inc:Demonstrate ability of Trovagene's molecular diagnostic platform to detect and monitor BRAF V600E mutations in cancer patients.Says BRAF V600E oncogene mutation assay was able to identify mutation in 29 patients (88 pct) at any time point during study, demonstrating high level of concordance with tissue biopsy.Says 25 of the 33 patients (76 pct) were positively identified for the mutation with their first urine sample.Longitudinal analysis was performed in 17 patients who had more than one urine-based test during the monitoring period.Of these patients, 13 (76 pct) showed correlation between response to treatment and mutational status observed by urine-based test.

Quest Diagnostics Inc's focus diagnostics receives FDA clearance for moderate complexity simplexa HSV 1 & 2 Direct molecular test for aiding the diagnosis of encephalitis

Monday, 24 Mar 2014 09:12am EDT

Quest Diagnostics Inc:Says its focus diagnostics products business has received expedited FDA 510(k) clearance and CLIA moderate complexity categorization for its new Simplexa HSV 1 & 2 Direct molecular test on the 3M Integrated Cycler.Encephalitis is an inflammation of the brain often caused by the herpes simplex or other viruses.

Cancer Genetics Inc announces new data for diagnosis and prediction of kidney cancer outcomes using its genomic test

Monday, 24 Feb 2014 07:30am EST

Cancer Genetics Inc:Announces new data that further validates its UroGenRA-Kidney diagnostic test for renal cell cancer will be presented at the annual United States & Canadian Academy of Pathology (USCAP) meeting on March 3rd in San Diego, CA.The new data was generated as part of a collaborative study conducted with the Cleveland Clinic in which 191 pathology specimens from renal cancer patients were provided and analyzed using the UroGenRA-Kidney test.

Ultrasis Plc announces new tool from U Squared Interactive

Friday, 20 Dec 2013 02:00am EST

Ultrasis Plc:Says U Squared Interactive, a JV between the University of Pittsburgh Medical Center Insurance Services (UPMC) and Ultrasis, is to release a newly-developed tool to estimate the health plan return-on-investment of providing on-line or computerized cognitive behavioral therapy (CCBT) to plan members.Says the estimation tool, which incorporates both individual health plan data and figures from Ultrasis' decade of experience with CCBT treatment in the United Kingdom, allows health plan managers to more accurately gauge the financial impact of adding CCBT as a benefit.

Enzo Biochem Inc Announces Study In Scientific Journal Linking Idiopathic Pulmonary Fibrosis

Friday, 15 Nov 2013 08:30am EST

Enzo Biochem Inc announced publication of a study in a scientific journal, Modern Pathology, a Nature Publishing Group publication, that shows a strong association of idiopathic pulmonary fibrosis (IPF), a pulmonary disease with 100% mortality within five years, with the presence of the herpesvirus saimiri virus, a virus native to squirrel monkeys. The discovery of the IPF`s origin is expected to result in a clinical diagnostic that could lead to screening and diagnosis, and perhaps result in potential treatment, for this fatal disease. The publication was authored by scientists from Enzo Biochem, Ohio State University, the Medical College of Wisconsin and Cornell University. The discovery is the subject of a patent application that is exclusively assigned to Enzo Biochem. Pulmonary fibrosis affects about one million people in the United States, of which IPF represents about 200,000 cases (20%). There is currently no effective way to diagnose IPF prior to the clinical manifestation of symptoms and treatments are largely ineffective. This new marker for IPF could address the urgent critical requirement for early diagnosis and screening of the pulmonary fibrosis population (over a million subjects). The goal of the study was to evaluate the role of the herpesviruses family in IPF. Researchers used 21 paraffin embedded lung biopsies from patients diagnosed with IPF, and 21 lung biopsies from age matched controls with pulmonary fibrosis that is not IPF.

Premier Inc Receives U.S. Patent For Hospital Supply Expense Analysis

Thursday, 14 Nov 2013 01:30pm EST

Premier, Inc announced that it has been granted a patent from the United States Patent and Trademark Office for its hospital supply expense methodology. Premier's newly patented Supply Mix Index allows users to calculate supply expense per patient procedure. Using the index, hospitals can accurately isolate supply costs as a percentage of the total cost of a clinical procedure and compare it with other hospitals nationwide to ensure appropriate resource utilization and supply efficiency, while identifying spending waste.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Market Edge
$10.00
Provider: Market Edge
$10.00
Provider: Auerbach Grayson & Co., Inc.
$25.00
Provider: Auerbach Grayson & Co., Inc.
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.